Capital Advisors Inc. OK Has $4.19 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Capital Advisors Inc. OK trimmed its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 34.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 203,775 shares of the company's stock after selling 107,270 shares during the quarter. Capital Advisors Inc. OK owned approximately 0.20% of Intellia Therapeutics worth $4,188,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Intellia Therapeutics by 8.9% during the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock valued at $250,168,000 after buying an additional 746,263 shares during the period. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 5.5% in the 2nd quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company's stock valued at $259,514,000 after purchasing an additional 606,507 shares during the period. Federated Hermes Inc. lifted its position in shares of Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock worth $51,494,000 after purchasing an additional 371,189 shares in the last quarter. Opaleye Management Inc. boosted its holdings in shares of Intellia Therapeutics by 157.6% during the first quarter. Opaleye Management Inc. now owns 255,000 shares of the company's stock worth $7,015,000 after purchasing an additional 156,000 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Intellia Therapeutics by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock valued at $29,648,000 after purchasing an additional 98,865 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Michael P. Dube sold 2,012 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the transaction, the chief accounting officer now owns 47,012 shares of the company's stock, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.20% of the stock is owned by company insiders.

Intellia Therapeutics Trading Up 4.1 %

Intellia Therapeutics stock traded up $0.59 on Friday, reaching $14.81. 1,800,843 shares of the stock were exchanged, compared to its average volume of 2,748,321. Intellia Therapeutics, Inc. has a twelve month low of $13.95 and a twelve month high of $34.87. The firm has a fifty day moving average price of $19.87 and a two-hundred day moving average price of $22.42. The stock has a market cap of $1.50 billion, a PE ratio of -2.70 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analysts' expectations of $19.68 million. The firm's revenue for the quarter was down 48.5% compared to the same quarter last year. During the same period last year, the firm posted ($1.40) EPS. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NTLA. Robert W. Baird cut their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. Evercore ISI upgraded Intellia Therapeutics to a "strong-buy" rating in a report on Friday, August 9th. Royal Bank of Canada restated an "outperform" rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Citigroup dropped their target price on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. Finally, Stifel Nicolaus reduced their price target on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating for the company in a report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $59.13.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.